Sana Biotechnology (NASDAQ:SANA) Downgraded by Wall Street Zen to Sell

Sana Biotechnology (NASDAQ:SANA) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Sunday.

A number of other research analysts also recently issued reports on SANA. Zacks Research downgraded Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 3rd. Wedbush increased their price objective on Sana Biotechnology from $6.00 to $7.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 14th. Rodman & Renshaw began coverage on Sana Biotechnology in a research report on Monday, May 11th. They set a “buy” rating and a $16.00 price objective for the company. Weiss Ratings cut Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. Finally, HC Wainwright decreased their price objective on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, March 4th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $9.50.

Sana Biotechnology Trading Down 9.5%

SANA stock opened at $2.68 on Friday. The company has a market capitalization of $745.82 million, a PE ratio of -2.88 and a beta of 2.14. Sana Biotechnology has a 12-month low of $2.41 and a 12-month high of $6.55. The business’s fifty day moving average price is $3.23 and its 200 day moving average price is $3.81.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.01. Research analysts predict that Sana Biotechnology will post -0.59 EPS for the current fiscal year.

Institutional Investors Weigh In On Sana Biotechnology

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC grew its position in Sana Biotechnology by 49.8% during the first quarter. AQR Capital Management LLC now owns 573,146 shares of the company’s stock valued at $963,000 after acquiring an additional 190,483 shares during the period. Woodline Partners LP grew its position in Sana Biotechnology by 13.1% during the first quarter. Woodline Partners LP now owns 780,656 shares of the company’s stock valued at $1,312,000 after acquiring an additional 90,515 shares during the period. Franklin Resources Inc. grew its position in Sana Biotechnology by 86.8% during the second quarter. Franklin Resources Inc. now owns 93,081 shares of the company’s stock valued at $254,000 after acquiring an additional 43,247 shares during the period. Rhumbline Advisers grew its position in Sana Biotechnology by 11.6% during the second quarter. Rhumbline Advisers now owns 203,283 shares of the company’s stock valued at $555,000 after acquiring an additional 21,149 shares during the period. Finally, Prudential Financial Inc. purchased a new stake in Sana Biotechnology during the second quarter valued at about $50,000. Hedge funds and other institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.